{ "items" : [
    { "id" : "http://dbpedia.org/resource/Vismodegib"
      "properties" : {
        "http://www.w3.org/2000/01/rdf-schema#comment" : [ "Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011." ] ,
        "http://xmlns.com/foaf/0.1/depiction" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Vismodegib2DACS.svg" ] ,
        "http://dbpedia.org/ontology/atcPrefix" : [ "L01" ] ,
        "http://dbpedia.org/ontology/atcSuffix" : [ "XX43" ] ,
        "http://dbpedia.org/ontology/bioavailability" : [ 31.79999923706055 ] ,
        "http://dbpedia.org/ontology/casNumber" : [ "879085-55-9" ] ,
        "http://dbpedia.org/ontology/chEBI" : [ "66903" ] ,
        "http://dbpedia.org/ontology/drugbank" : [ "DB08828" ] ,
        "http://dbpedia.org/ontology/fdaUniiCode" : [ "25X868M3DS" ] ,
        "http://dbpedia.org/ontology/iupacName" : [ "2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide" ] ,
        "http://dbpedia.org/ontology/pubchem" : [ "24776445" ] ,
        "http://dbpedia.org/ontology/thumbnail" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Vismodegib2DACS.svg?width=300"] } } }
